West Pharma Q2 net sales $753.8M (-2.3%), adjusted EPS $2.11; raises FY2023 guidance

WEST PHARMACEUTICAL SERVICES INC

2023-Q2 EPS reported $3.91 revenue$1,470,400,000

Reported Q2 diluted EPS of $2.06; adjusted diluted EPS of $2.11, down from $2.47 YoY.
Net sales declined 2.3% to $753.8M; organic net sales fell 2.5%.
Proprietary Products segment sales down 5.5% to $618.0M, driven by COVID-19 related decline; base business grew double digits.
Contract-Manufactured Products segment sales up 15.3% to $135.8M, led by injection-device components.
FY2023 net sales guidance raised to $2.970-2.995B; adjusted EPS guidance raised to $7.65-7.80.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

WEST PHARMACEUTICAL SERVICES INC reported second-quarter 2023 results: revenue $753.8 million, EPS $2.06. Guidance raised.

Period: second-quarter 2023
Revenue: $753.8 million
EPS: $2.06
Guidance: raised
Result: reported results

Exact text from the filing

West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the second-quarter 2023 and updated full-year 2023 financial guidance. Second-Quarter 2023 Summary (comparisons to prior-year period) • Net sales of $753.8 million declined 2.3%; organic net sales declined 2.5%. • Reported-diluted EPS of $2.06, compared to $2.48 in the same period last year.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

WEST PHARMACEUTICAL SERVICES INC filing history →

Source: SEC EDGAR

accession 0000105770-23-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.